Pfizer’s sales of its COVID-19 vaccine, Comirnaty, fell sharply by 25% in the U.S. during the third quarter of 2025, dropping to $870 million from $1.16 billion in the same period last year.

This significant sales decline follows the U.S. government’s decision to narrow its guidance on who should receive COVID-19 vaccine shots.

Driving the news: The Centers for Disease Control and Prevention (CDC) stopped recommending COVID-19 vaccinations for the general population, leaving the decision up to individual patients starting in late 2025. • The CDC’s updated guidance aligns with recommendations made by advisers appointed by U.S. Health Secretary Robert F. Kennedy Jr. • Previously, U.S. health officials advised annual COVID-19 booster shots for all Americans aged 6 months and older, aimi

See Full Page